Subscribe To
Nzd/usd dec 2023
2-Year U.S. Treasury Note Continuous Contract $101.602-0.023-0.02% 5-Year U.S. Treasury Note Continuous Contract $106.195-0.031-0.03% 10-Year U.S. Tre...
October 3, 2023, 1:59 am
Exxonmobil (xom) banned from trucking california offshore oil
ExxonMobil (XOM) proposes to dispatch as many as 24,820 tanker trucks per year along coastal Highway 101 ...
September 28, 2023, 12:02 pm
Verve to present interim data from the heart-1 phase 1b clinical trial of verve-101 in hefh patients at the american heart association’s scientific sessions 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023 BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) — Verve Therapeuti...
September 26, 2023, 10:30 am
Building credit 101: a beginner's guide
Building and maintaining good credit is a fundamental aspect of personal finance. A good credit history can lead to lower loan interest rates, credit ...
September 26, 2023, 10:17 am
Biophytis (bpts) soars 73% on partnership with skyepharma
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101)....
September 26, 2023, 9:01 am
Verve to present interim data from the heart-1 phase 1b clinical trial of verve-101 in hefh patients at the american heart association's scientific sessions 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023 Company to hold investor event in conjunction with data pres...
September 26, 2023, 6:30 am
Pds biotech reschedules key opinion leader roundtable addressing current and future treatments for recurrent/metastatic hpv-positive hnscc and the potential application of pds0101
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Na...
September 25, 2023, 12:00 pm
Biophytis shares surge 41% following covid partnership with france's skyepharma
Shares of Biophytis (NASDAQ:BPTS, EPA:ALBPS), a clinical-stage biotechnology firm, soared 41% in premarket trading on Nasdaq following the announcemen...
September 25, 2023, 9:12 am
Whatever happened to gold being an inflation hedge?
Having just come back from New York my eyeballs still hurt from them bugging out at prices. You can’t say the same about gold. So I’ve thrown out ...
September 22, 2023, 1:14 pm
Relmada (rlmd) up on positive data for anti-depressant candidate
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with ma...
September 21, 2023, 3:02 pm
E-mini eur/usd mar 2024
2-Year U.S. Treasury Note Continuous Contract $101.352-0.094-0.09% 5-Year U.S. Treasury Note Continuous Contract $105.648-0.258-0.24% 10-Year U.S. Tre...
September 19, 2023, 8:44 pm
Nasdaq index falls to the lowest level since august 25
The NASDAQ index is falling to new session lows. The index is currently down -101 points or -0.73% at 1...
September 19, 2023, 2:12 pm
Vigil neuroscience: interesting early data, wait for phase 2
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclo...
September 18, 2023, 2:38 pm
Packaging corporation of america schedules conference call to discuss third quarter 2023 operating results
LAKE FOREST, Ill.--(BUSINESS WIRE)--Packaging Corporation of America (NYSE: PKG) will hold a conference call on Tuesday, October 24, 2023 at 9:00 a.m....
September 18, 2023, 11:27 am
23andme and sickle cell 101 collaborate to expand sickle cell awareness program
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry...
September 14, 2023, 11:00 am
Sensei biotherapeutics to present new preclinical data supporting mechanism of action, pharmacokinetic profile and safety characteristics for sns-101, a conditionally active vista-blocking antibody, a
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the disco...
September 13, 2023, 11:30 am
Moderna says flu vaccine showed promising results in phase three trial, paving path to approval
Moderna compared the flu vaccine, dubbed mRNA-1010, to a currently approved seasonal flu vaccine from GlaxoSmithKline called Fluarix....
September 13, 2023, 8:19 am
Nevada lithium commences 2023 diamond drill program at bonnie claire lithium project
Nevada Lithium Resources Inc (CSE:NVLH, OTCQB:NVLHF) told investors that drilling has commenced at Bonnie Claire as the company targets a pre-feasibil...
September 12, 2023, 8:36 am
Dyne therapeutics: muscle disease oligo therapy developer in early stages
Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular D...
September 10, 2023, 5:25 am
Okyo pharma completes enrollment in phase 2 clinical trial to treat dry eye disease
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center, doubl...
September 8, 2023, 8:35 am